Posted on Leave a comment

Obstructive Sleep Apnea Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies|Companies-Teva Pharmaceuticals, Jazz Pharmaceuticals, Idorsia Pharmaceuticals, Bayer, Apnimed

Obstructive Sleep Apnea Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies|Companies-Teva Pharmaceuticals, Jazz Pharmaceuticals, Idorsia Pharmaceuticals, Bayer, Apnimed
DelveInsight Business Research L

DelveInsight’s “Obstructive Sleep Apnea (OSA) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Obstructive Sleep Apnea (OSA), historical and forecasted epidemiology as well as the Obstructive Sleep Apnea (OSA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Obstructive Sleep Apnea (OSA) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Obstructive Sleep Apnea (OSA), historical and forecasted epidemiology as well as the Obstructive Sleep Apnea (OSA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The Obstructive Sleep Apnea (OSA) market report provides current treatment practices, emerging drugs, Obstructive Sleep Apnea (OSA) market share of the individual therapies, current and forecasted Obstructive Sleep Apnea (OSA) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Obstructive Sleep Apnea (OSA) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Obstructive Sleep Apnea (OSA) market.

Some of the key facts of the Obstructive Sleep Apnea Market

  • The Prevalence of OSA was 24% in men and 9% in women aged 30-60 years of age. 

  • The prevalence of OSA with associated excessive daytime somnolence is approximately 3% to 7% in adult men and 2% to 5% in adult women. Prevalence estimates don’t vary significantly worldwide suggesting that OSA is as common in the developing world as in Western society.

Got queries? Click here to know more about the Obstructive Sleep Apnea Market Landscape

Obstructive Sleep Apnea Overview

Obstructive sleep apnea (OSA) is a common, chronic, sleep-related breathing disorder characterized by periodic narrowing and obstruction of the pharyngeal airway during sleep, leading to either complete or partial obstruction of the airway, resulting in apneas, hypopneas, or both. This disorder causes daytime somnolence, neurocognitive defects, and depression. OSA affects almost every system in the body, resulting in an increased incidence of hypertension, cardiovascular disease, stroke, pulmonary hypertension, cardiac arrhythmias, and altered immune function. It also increases the risk of having an accident, presumably as a result of associated somnolence. According to the American Academy of Sleep Medicine, OSA is a sleep-related breathing disorder that involves a decrease or complete halt in airflow despite an ongoing effort to breathe. It occurs when the muscles relax during sleep, causing soft tissue in the back of the throat to collapse and block the upper airway. Current evidence suggests that disturbances in PCRIT play a primary role in OSA pathogenesis. The role of pharyngeal obstruction in OSA pathogenesis can be considered in light of Koch’s postulates, which establish criteria for demonstrating a causal relationship between pathogenic factors that promote upper airway obstruction and the overt polysomnographic manifestation of the disease. These principles require first and foremost that pathogenic factors causing upper airway collapse are associated with OSA. 

 Obstructive Sleep Apnea Epidemiology Insights

  • Prevalence estimates from studies in three regions i.e. Wisconsin, Pennsylvania, and Spain with probability samples range, for OSA of at least mild severity (defined by AHI ⩾ 5), from 3 to 28%; for OSA of at least moderate severity (defined by AHI ⩾ 15), estimates range from 1 to 14% (Young et al., 2002).

  • Roughly 175 million Europeans have obstructive sleep apnea, according to an presented by ResMed at the European Respiratory Society’s (ERS) annual ERS Congress in Paris. Leading researchers estimate 90 million Europeans have moderate to severe sleep apnea, meaning they experience at least 15 breathing events an hour during sleep. 

 Obstructive Sleep Apnea Epidemiology Segmentation

  • Obstructive Sleep Apnea diagnosed cases 

  • Obstructive Sleep Apnea incident cases  

  • Obstructive Sleep Apnea prevalent cases 

  • Primary Billary Cirrhosis treatment cases 

Obstructive Sleep Apnea Market Outlook 

The Obstructive Sleep Apnea (OSA) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Obstructive Sleep Apnea (OSA) market trends by analyzing the impact of current Obstructive Sleep Apnea (OSA) therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Obstructive Sleep Apnea (OSA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Obstructive Sleep Apnea (OSA) market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Obstructive Sleep Apnea (OSA) market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @ Obstructive Sleep Apnea Market Trends

 Obstructive Sleep Apnea Key Companies

  • Teva Pharmaceuticals

  • Jazz Pharmaceuticals

  • Idorsia Pharmaceuticals

  • Bayer

  • Apnimed

  • And many others 

Obstructive Sleep Apnea Therapies

  • Apnimed 

  • Nyoxa Inc 

  • Idorisia Pharmaceuticals 

  • And many others 

Table of Contents

  1.  Key Insights 

  2.  Report Introduction 

  3.  Executive Summary of Obstructive Sleep Apnea     

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  The United States 

  7.  EU 5

  8.  Obstructive Sleep Apnea Emerging Therapies

  9.  Obstructive Sleep Apnea Market Outlook

  10.  Market Access and Reimbursement of Therapies

  11.  Market Drivers 

  12.  Market Barriers 

  13.  Appendix

  14.  Obstructive Sleep Apnea   Report Methodology

  15.  DelveInsight Capabilities

  16.  Disclaimer

Click here to read more about Obstructive Sleep Apnea Market 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services